Keros Therapeutics (KROS) Stock Forecast & Price Target

Compare

339 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KROS Analyst Ratings

Moderate Buy

5 Buy

5 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Keros

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KROS Stock 12 Month Forecast

Average Price Target

$24.17

▲(77.20%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $24.17 with a high forecast of $35.00 and a low forecast of $15.00. The average price target represents a 77.20% change from the last price of $13.64.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","21":"$21","34":"$34","47":"$47","60":"$60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,21,34,47,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.66,16.224615384615383,17.78923076923077,19.353846153846153,20.91846153846154,22.483076923076922,24.04769230769231,25.61230769230769,27.176923076923075,28.74153846153846,30.306153846153848,31.87076923076923,33.43538461538461,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.66,15.391538461538461,16.123076923076923,16.854615384615386,17.58615384615385,18.317692307692308,19.04923076923077,19.78076923076923,20.512307692307694,21.243846153846157,21.975384615384616,22.70692307692308,23.43846153846154,{"y":24.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.66,14.686153846153847,14.712307692307693,14.73846153846154,14.764615384615384,14.79076923076923,14.816923076923077,14.843076923076923,14.86923076923077,14.895384615384616,14.92153846153846,14.947692307692307,14.973846153846154,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.72,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.87,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.79,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$24.17

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$14

Hold

2.64%

Upside

Reiterated

06/10/25

Keros Therapeutics has a low overall stock score due to several factors. Financial performance is hindered by ongoing unprofitability and negative cash flows, which are typical of growth-stage biotech firms. Although technical analysis indicates some positive momentum, valuation remains challenged by the lack of profitability. Significant negative corporate events, including a major workforce reduction and strategic realignment, further weigh on the overall score.

Jason ZemanskyBank of America Securities

Bank of America Securities

$18

Hold

31.96%

Upside

Reiterated

06/10/25

Keros Therapeutics downgraded to Neutral from Buy at BofAKeros Therapeutics downgraded to Neutral from Buy at BofA

Greg HarrisonScotiabank

Scotiabank

$26

Buy

90.62%

Upside

Reiterated

06/10/25

Keros Therapeutics (KROS) Receives a Buy from Scotiabank

Tiago FauthWells Fargo

Wells Fargo

$28→$26

Buy

90.62%

Upside

Reiterated

06/09/25

Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/30/25

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

Yun ZhongWedbush

Wedbush

$15

Hold

9.97%

Upside

Reiterated

05/30/25

Hold Rating on Keros Therapeutics Amid Strategic Review and Clinical Setbacks

Thomas SmithLeerink Partners

Leerink Partners

$35

Buy

156.60%

Upside

Reiterated

05/29/25

Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)

Vamil DivanGuggenheim

Guggenheim

―

Hold

―

Reiterated

05/29/25

Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

05/29/25

William Blair Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$40→$25

Buy

83.28%

Upside

Reiterated

05/08/25

Keros Therapeutics price target lowered to $25 from $40 at H.C. WainwrightKeros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright

Tyler Van BurenTD Cowen

TD Cowen

―

Hold

―

Reiterated

05/06/25

Keros Therapeutics: Promising Developments Amidst Uncertainties Lead to Hold Rating

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Hold

―

Downgraded

01/21/25

Keros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldKeros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Joseph CatanzaroPiper Sandler

Piper Sandler

$40→$15

Buy

9.97%

Upside

Reiterated

01/17/25

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

Andreas ArgyridesOppenheimer

Oppenheimer

$63→$23

Buy

68.62%

Upside

Reiterated

01/15/25

Keros Therapeutics (KROS) Receives a Buy from Oppenheimer

Kelly ShiJefferies

Jefferies

$113→$23

Buy

68.62%

Upside

Reiterated

12/13/24

Keros Therapeutics (KROS) PT Lowered to $23 at JefferiesJefferies analyst Kelly Shi lowered the price target on Keros Therapeutics (NASDAQ: KROS) to $23.00 (from $113.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$14

Hold

2.64%

Upside

Reiterated

06/10/25

Jason ZemanskyBank of America Securities

Bank of America Securities

$18

Hold

31.96%

Upside

Reiterated

06/10/25

Keros Therapeutics downgraded to Neutral from Buy at BofAKeros Therapeutics downgraded to Neutral from Buy at BofA

Greg HarrisonScotiabank

Scotiabank

$26

Buy

90.62%

Upside

Reiterated

06/10/25

Keros Therapeutics (KROS) Receives a Buy from Scotiabank

Tiago FauthWells Fargo

Wells Fargo

$28→$26

Buy

90.62%

Upside

Reiterated

06/09/25

Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/30/25

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

Yun ZhongWedbush

Wedbush

$15

Hold

9.97%

Upside

Reiterated

05/30/25

Hold Rating on Keros Therapeutics Amid Strategic Review and Clinical Setbacks

Thomas SmithLeerink Partners

Leerink Partners

$35

Buy

156.60%

Upside

Reiterated

05/29/25

Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)

Vamil DivanGuggenheim

Guggenheim

―

Hold

―

Reiterated

05/29/25

Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

05/29/25

William Blair Sticks to Their Hold Rating for Keros Therapeutics (KROS)

Andres Y. MaldonadoH.C. Wainwright

H.C. Wainwright

$40→$25

Buy

83.28%

Upside

Reiterated

05/08/25

Keros Therapeutics price target lowered to $25 from $40 at H.C. WainwrightKeros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright

Tyler Van BurenTD Cowen

TD Cowen

―

Hold

―

Reiterated

05/06/25

Keros Therapeutics: Promising Developments Amidst Uncertainties Lead to Hold Rating

Prakhar AgrawalCantor Fitzgerald

Cantor Fitzgerald

―

Hold

―

Downgraded

01/21/25

Keros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldKeros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Joseph CatanzaroPiper Sandler

Piper Sandler

$40→$15

Buy

9.97%

Upside

Reiterated

01/17/25

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

Andreas ArgyridesOppenheimer

Oppenheimer

$63→$23

Buy

68.62%

Upside

Reiterated

01/15/25

Keros Therapeutics (KROS) Receives a Buy from Oppenheimer

Kelly ShiJefferies

Jefferies

$113→$23

Buy

68.62%

Upside

Reiterated

12/13/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Keros Therapeutics

1 Month

xxx

Success Rate

13/22 ratings generated profit

Average Return

+3.95%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +3.95% per trade.

3 Months

xxx

Success Rate

12/22 ratings generated profit

Average Return

+21.45%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +21.45% per trade.

1 Year

Joseph CatanzaroPiper Sandler

Success Rate

11/22 ratings generated profit

Average Return

+4.63%

reiterated a buy rating 5 months ago

Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.63% per trade.

2 Years

xxx

Success Rate

9/28 ratings generated profit

Average Return

-32.50%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 32.14% of your transactions generating a profit, with an average return of -32.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KROS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KROS has received 15 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. KROS average Analyst price target in the past 3 months is 24.17.

Each month's total comprises the sum of three months' worth of ratings.

KROS Financial Forecast

KROS Earnings Forecast

Next quarter’s earnings estimate for KROS is -$1.13 with a range of -$1.35 to -$0.71. The previous quarter’s EPS was $3.62. KROS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year KROS has Outperformed its overall industry.

KROS Sales Forecast

Next quarter’s sales forecast for KROS is $4.21M with a range of $0.00 to $20.00M. The previous quarter’s sales results were $211.25M. KROS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year KROS has Outperformed its overall industry.

KROS Stock Forecast FAQ

What is KROS’s average 12-month price target, according to analysts?

Based on analyst ratings, Keros Therapeutics’s 12-month average price target is 24.17.

What is KROS’s upside potential, based on the analysts’ average price target?

Keros Therapeutics has 77.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KROS a Buy, Sell or Hold?

Keros Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 5 hold ratings and 0 sell ratings.

What is Keros Therapeutics’s price target?

The average price target for Keros Therapeutics is 24.17. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $15.00. The average price target represents 77.20% Increase from the current price of $13.64.

What do analysts say about Keros Therapeutics?

Keros Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of KROS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Keros Therapeutics (KROS) Stock Forecast & Price Target

KROS Analyst Ratings

KROS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Keros Therapeutics

KROS Analyst Recommendation Trends

KROS Financial Forecast

KROS Earnings Forecast

KROS Sales Forecast

KROS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts